Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.49 |
| ▸ | CTSD | P07339 | 3/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 13/20 | 0.49 |
| ▸ | UBE2M | P61081 | 11/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7541442 | 0.91 | BACE1 (0.54) | BACE1CTSDDCUN1D1UBE2MEPHX2 | |
| SCHEMBL7537996 | 0.90 | BACE1 (0.56) | BACE1CTSDEPHX2KMT2A | |
| SCHEMBL7539241 | 0.88 | CCR3 (0.51) | BACE1CTSDMEN1KMT2A | |
| SCHEMBL7539672 | 0.87 | CXCR3 (0.51) | BACE1CTSDEPHX2 | |
| SCHEMBL11934210 | 0.87 | CXCR3 (0.51) | BACE1CTSDEPHX2 | |
| SCHEMBL8266664 | 0.85 | BACE1 (0.54) | BACE1CTSDKMT2A | |
| SCHEMBL7536847 | 0.84 | BACE1 (0.56) | BACE1CTSDEPHX2MEN1KMT2A | |
| SCHEMBL12173877 | 0.83 | BACE1 (0.66) | BACE1CTSDEPHX2 | |
| SCHEMBL8198984 | 0.83 | BACE1 (0.66) | BACE1CTSDEPHX2 | |
| SCHEMBL7540070 | 0.83 | BACE1 (0.66) | BACE1CTSDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885CTSD 13/4885DCUN1D1 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.